Alnylam Pharmaceuticals | ALNY - Cost Of Sales


Alnylam Pharmaceuticals reported $211.12M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amgen USD 1.6B 187M Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Moderna USD 955M 503M Mar/2026
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Novartis USD 3.46B 83M Mar/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.14B 618M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Takeda JPY 560.54B 159.39B Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026
Xencor USD 61.66M 50.95M Jun/2025